Sign In
NewsRadar

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.

   


AM-Pharma announces EURO 7 million first close of series C financing round
Existing investors support AM-Pharma and set the terms for second close


Bunnik, The Netherlands, 29 May 2008. AM-Pharma B.V., the biopharmaceutical company developing improved endogenous proteins and peptides to combat disease, today announced the signing of a EURO 7 million financing agreement with Forbion Capital Partners and Inventages Venture Capital.

The announced investment is a First Close of a Series C financing round of EURO 20 million. AM-Pharma is in active discussion with several potential investors from both Europe and the US on the investment of another EURO 13million in a Second Close of the Series C financing round. Investors in the Second Close will be allowed to invest at the same terms and conditions that apply to this First Close.

Cash raised in this C round will allow the company to generate further Phase II efficacy and safety data for its two products; Recombinant human Alkaline Phosphatase and Selective Immune Response Amplifying peptide hLF1-11, in three therapeutic indications; Acute Renal Failure; Ulcerative Colitis and hospital acquired infections. The results of these Phase II trials, which will become available within the next three years, are expected to significantly boost the value of AM-Pharma.

AM-Pharma recently announced positive results in two Phase IIa studies with Alkaline Phosphatase in Acute Renal Failure and Ulcerative Colitis, whilst Selective Immune Response Amplifier hLF1-11 showed to be safe in Phase I trials and in a first trial against infections in bone marrow transplant patients.

Bart Wuurman, CEO commented: “It’s great that investors continue to support us in moving our clinical programmes forward. With the upcoming Second Close of our C round we are offering new investors an exciting opportunity to invest on attractive terms at a time when a strong upswing in company value could be very near.

Gunnar Weikert, Chairman of Inventages added: “The clinical progress and data shown so far by the company are very encouraging. This is one of the few companies that have three products in Phase II development and an experienced team in place to maximize their value.”

Bart Bergstein of Forbion Capital Partners pointed out: “AM-Pharma has reached the typical period where value inclination points will be reached. Given the strong pipeline, the expectation of a liquidity event via an IPO or trade sale in the upcoming period is more realistic than ever.”


Notes to editors:

About AM-Pharma www.am-pharma.com

AM-Pharma is a biopharmaceutical company focused on the preclinical and clinical development of novel compounds in the field of severe infectious diseases and inflammatory diseases. All its products are based on optimized endogenous molecules which combat disease using physiological defence mechanisms. AM-Pharma is conducting Phase II clinical trials for two products; Alkaline Phosphatase for acute renal failure and ulcerative colitis; and Selective Immune Response Amplifying peptide hLF1-11 for the treatment of drug resistant hospital acquired infections. AM-Pharma is based in Bunnik, The Netherlands with a staff of 15. The company is financed by, amongst others, Forbion Capital Partners and Inventages Venture Capital. Once product safety and efficacy have been established in Phase II trials, AM-Pharma will look for world-wide development and marketing partners for its products.

About Inventages www.inventages.com

Inventages Venture Capital is one of the world’s largest venture/private equity funds specializing in life sciences, with more than $1.5 billion under management. Inventages’ investment focus includes pharmaceuticals, nutraceuticals, medical food, nutrition, cosmeceuticals, innovative food, as well as, consumer relation management, processes and novel packaging technologies. Inventages operates from three offices around the globe in Auckland, Geneva and Nassau.

About Forbion www.forbion.com

Forbion Capital Partners invests in EU and US Life Sciences companies with a focus on drug development and medical technologies. The Forbion team has made life sciences investments since 2000 as ABN AMRO Capital Life Sciences, the venture arm of ABN AMRO Bank NV. In December of 2006 the group became independent by broadening its investor base and changed its name to Forbion Capital Partners. Since 2000, the Forbion team has successfully divested a number of investments, leaving an active portfolio now comprising 24 companies. Assets under management currently total €200 M.

For further information, please contact

College Hill Life Sciences
Adam Michael / Justine Lamond
Tel: +44 (0)20 7866 7857
justine.lamond@collegehill.com

AM-Pharma
CEO Bart Wuurman
Tel: +31 (0)30 2289222
www.am-pharma.com


Publisher Contact Information:

AM-Pharma BV
+31 (0)30 2289222
-

Company profile of AM-Pharma BV
Past press releases of AM-Pharma BV.

Data


25,720
Tech investments
From our Online Data Service
16,652
VC-backed companies
From our Radar


Recent Deals


DATEAMOUNTSECTOR
May 17€4.0MBiopharmaceuticals
May 16€15.0MPayment software
May 16€4.0MInternet services
May 16€80.0MConsumer electronics
May 16€6.3MImaging
May 16€13.0MInternet services
May 16€34.5MBiotechnology

For information on Europe's most extensive database on technology funding click here!

Events



Press Releases


Apr 29
Nethone
nethone raised over $1 million from innovation nest

Oct 1
The Link App
the link app launches version 2.0

Mar 29
Addex Therapeutics
addex sucessfully raises chf40 million in capital increase

Jan 2
Urban Jungle
urban jungle raises £1m in seed funding to build tech-enabled home ...

Aug 17
Komed Health
komed health closes seed financing round





About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.